Follow us...

 

Search News Archives

News Channels

 

Special Offers and Promotions

 

 

Laboratory Products

 

 

View Channel

News

 

 

View Channel

Microscopy | Image Analysis

 

 

View Channel

Separation Science

 

 

View Channel

Research & Case Studies

 

 

View Channel

Coronavirus (COVID-19)

 

 

View Channel

Brochures & Literature

 

 

View Channel

 

Conferences | Events

Jubilant Biosys and Yale University announce collaboration to accelerate multiple small molecule discovery programs

publication date: Mar 22, 2021
 | 
author/source: Jubilant Biosys

jubilant_biosys_and_yale_university_announce_collaborat

 

Jubilant Biosys and Yale University have announced a research collaboration for multiple small molecule research programs.

Under the scope of this partnership, Jubilant Biosys will provide research services to investigators at Yale University working on novel therapeutic targets. Areas of collaboration include medicinal chemistry, structural biology, in-vitro and in-vivo pharmacology among others.

Commenting on this collaboration, Marcel Velterop, President Jubilant Biosys said “Yale is one of the top-ranked academic institutions in the US and we at Jubilant Biosys are delighted to be able to support scientific endeavors of Investigators at Yale to pursue novel target ideas for unmet medical conditions. With our New Discovery Chemistry Site scheduled to commence operations in 2021, we will further add to our capability a new infrastructure to service our partners.”

“Our CRO relationships are an integral component in our pursuit of helping Yale’s scientific community transition their research towards commercialization, and we are pleased to have Jubilant Biosys join our entrepreneurial ecosystem,” said Bill Wiesler, Director of New Ventures and the Blavatnik Fund for Innovation at Yale, Office of Cooperative Research.

 

About Jubilant Biosys Limited

Jubilant Biosys, a subsidiary of Jubilant Pharmova Limited, an integrated global pharmaceutical company, has a presence in Bengaluru and Noida in India. Jubilant Biosys offers contract research & development services for global pharmaceutical innovators. Biosys has demonstrated expertise in functional services such as Biology, DMPK, Toxicology as well as Medicinal Chemistry and PR&D, SPR, and GMP scale-up capabilities up to phase II. It has integrated discovery expertise with a track record of over 75 programs in multiple therapeutic areas including but not limited to Oncology, Metabolic Disorders, Pain & Inflammation, CNS and expanding into Rare Diseases. In addition, it markets “TrialStat™”, a proprietary and flexible clinical trial data capture software and has started AI/ML activities in drug discovery under its Digital initiative.

 

more news from Jubilant Biosys


 


If you have not logged into the website then please enter your details below.


 

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partner